Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Medicine
|
| gptkbp:administered_by |
transducer arrays
|
| gptkbp:advocacy |
important for awareness
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:can_be_combined_with |
chemotherapy
|
| gptkbp:clinical_trial |
ongoing
Phase III published in journals positive outcomes in trials encouraged for patients. |
| gptkbp:clinical_use |
integrated into oncology care
|
| gptkbp:collaborations |
with pharmaceutical companies
with cancer centers |
| gptkbp:developed_by |
gptkb:Novocure
|
| gptkbp:device_maintenance |
required for effectiveness
|
| gptkbp:duration |
months to years
|
| gptkbp:duration_of_treatment |
continuous use
|
| gptkbp:eligibility |
specific criteria
|
| gptkbp:feedback |
mixed reviews
|
| gptkbp:financial_support |
available resources
|
| gptkbp:funding |
grants and investments
|
| gptkbp:future_prospects |
exploring new applications
|
| https://www.w3.org/2000/01/rdf-schema#label |
tumor-treating fields
|
| gptkbp:invention |
patented technology
|
| gptkbp:is_effective_against |
varies by tumor type
|
| gptkbp:is_monitored_by |
required during treatment
|
| gptkbp:marketed_as |
gptkb:Optune
|
| gptkbp:mechanism_of_action |
electromagnetic fields
disrupts mitosis |
| gptkbp:origin |
gptkb:Israel
|
| gptkbp:patient_compliance |
critical for success
|
| gptkbp:patient_education |
important for adherence
|
| gptkbp:price |
high
|
| gptkbp:provides_guidance_on |
outpatient
provided by manufacturers included in treatment protocols |
| gptkbp:publication |
numerous studies
|
| gptkbp:recruitment |
based on tumor characteristics
|
| gptkbp:regulatory_compliance |
international markets
|
| gptkbp:research_focus |
solid tumors
|
| gptkbp:research_institutes |
collaborating with universities
|
| gptkbp:side_effect |
fatigue
skin irritation |
| gptkbp:suitable_for |
non-dividing cells
|
| gptkbp:target_audience |
adults
|
| gptkbp:targets |
dividing cancer cells
|
| gptkbp:technology |
gptkb:medical_devices
|
| gptkbp:training |
necessary for implementation
|
| gptkbp:treatment |
monitored over time
continues to evolve improved survival rates control tumor growth |
| gptkbp:treatment_accessibility |
limited in some regions
|
| gptkbp:treatment_innovation |
ongoing development
|
| gptkbp:treatment_limitations |
not suitable for all patients
|
| gptkbp:type_of_insurance |
varies by provider
|
| gptkbp:used_for |
treating cancer
|
| gptkbp:used_in |
glioblastoma treatment
|
| gptkbp:bfsParent |
gptkb:Oncology
|
| gptkbp:bfsLayer |
4
|